- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Taysha Gene Therapies Inc (TSHA)
Taysha Gene Therapies Inc stock price live, this page displays NASDAQ TSHA stock exchange data. View the TSHA premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Taysha Gene Therapies Inc real time stock price chart below.
What Is the Taysha Gene Therapies Inc Stock Price Today?
The Taysha Gene Therapies Inc stock price today is 5.651.
What Is the Stock Symbol for Taysha Gene Therapies Inc?
The stock ticker symbol for Taysha Gene Therapies Inc is TSHA.
Is TSHA the Same as $TSHA?
$TSHA is a common way to refer to the Taysha Gene Therapies Inc ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Taysha Gene Therapies Inc Trade On?
Taysha Gene Therapies Inc is listed and trades on the NASDAQ stock exchange.
Is Taysha Gene Therapies Inc a Good Stock to Buy?
Determining whether Taysha Gene Therapies Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Taysha Gene Therapies Inc share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the TSHA quote. (ISIN: US8776191061)
What Is the Taysha Gene Therapies Inc Stock Price Today?
The Taysha Gene Therapies Inc stock price today is 5.651.
What Is the Stock Symbol for Taysha Gene Therapies Inc?
The stock ticker symbol for Taysha Gene Therapies Inc is TSHA.
Is TSHA the Same as $TSHA?
$TSHA is a common way to refer to the Taysha Gene Therapies Inc ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Taysha Gene Therapies Inc Trade On?
Taysha Gene Therapies Inc is listed and trades on the NASDAQ stock exchange.
Is Taysha Gene Therapies Inc a Good Stock to Buy?
Determining whether Taysha Gene Therapies Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Taysha Gene Therapies Inc share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the TSHA quote. (ISIN: US8776191061)
5.651
+0.941(+19.97%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.720
5.655
52 wk Range
1.130
6.020
TSHA is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.7205.655
52 wk Range
1.1306.020
Key Statistics
Edit
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
TSHA Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
11.571
Upside
+104.77%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts do not anticipate the company will be profitable this year
- Form 144 Taysha Gene Therapies For: 10 April
- Investing.com
- Form 144 Taysha Gene Therapies For: 10 April
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
Taysha Gene Therapies Inc SWOT Analysis
Market Momentum | Analysts set price targets ranging from $5 to $7, reflecting optimism in Taysha's potential to capture significant market share in rare disease treatments |
Financial Fortitude | $312.8M cash balance supports operations into 2028, with analysts projecting potential revenues exceeding $2B for Rett syndrome treatment |
Regulatory Fast Track | FDA alignment on pivotal trial design and RMAT designation accelerate Taysha's path to potential approval, bypassing traditional development stages |
Promising Pipeline | Taysha's TSHA-102 for Rett syndrome shows 100% response rate in trials, positioning the company as a frontrunner in gene therapy for CNS disorders |
Taysha Gene Therapies Inc Earnings Call Summary for Q4/2025
- Taysha reported FY 2025 net loss of $109M ($0.34/share), up from $89.3M loss in 2024, driven by 30.9% surge in R&D expenses.
- Cash position of $319.8M expected to fund operations into 2028, providing runway for continued clinical development initiatives.
- TSHA-102 Rett syndrome trial showed 100% response rate in high-dose patients; dosing completion expected in 2026 as key milestone.
- Stock gained 6.52% premarket despite widened loss, reflecting investor optimism; shares delivered 143% return over past year.
- Management emphasized commitment to broad access and affordability for TSHA-102 while building commercial infrastructure for launch.
Last Updated: 03/19/2026, 09:48 AM
Read Full TranscriptCompare TSHA to Peers and Sector
Metrics to compare | TSHA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipTSHAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −13.6x | −8.8x | −0.5x | |
PEG Ratio | −2.76 | −0.27 | 0.00 | |
Price / Book | 6.0x | 3.2x | 2.6x | |
Price / LTM Sales | 151.5x | 18.4x | 3.2x | |
Upside (Analyst Target) | 144.2% | 61.6% | 47.6% | |
Fair Value Upside | Unlock | −7.8% | 6.1% | Unlock |
Analyst Ratings
14 Buy
0 Hold
0 Sell
Ratings:
14 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 11.571
(+104.77% Upside)
Earnings
Latest Release
Mar 19, 2026
EPS / Forecast
-0.08 / -0.10
Revenue / Forecast
5.48M / 2.22M
People Also Watch
FAQ
What Is the Taysha Gene (TSHA) Stock Price Today?
The Taysha Gene stock price today is 5.651 USD.
What Stock Exchange Does Taysha Gene Trade On?
Taysha Gene is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Taysha Gene?
The stock symbol for Taysha Gene is "TSHA."
What Is the Taysha Gene Market Cap?
As of today, Taysha Gene market cap is 1.610B USD.
What Is Taysha Gene's Earnings Per Share (TTM)?
The Taysha Gene EPS (TTM) is -0.341.
When Is the Next Taysha Gene Earnings Date?
Taysha Gene will release its next earnings report on May 20, 2026.
From a Technical Analysis Perspective, Is TSHA a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Taysha Gene Stock Split?
Taysha Gene has split 0 times.
How Many Employees Does Taysha Gene Have?
Taysha Gene has 99 employees.
What is the current trading status of Taysha Gene (TSHA)?
As of Apr 15, 2026, Taysha Gene (TSHA) is trading at a price of 5.651 USD, with a previous close of 4.710 USD. The stock has fluctuated within a day range of 4.720 USD to 5.655 USD, while its 52-week range spans from 1.130 USD to 6.020 USD.
What Is Taysha Gene (TSHA) Price Target According to Analysts?
The average 12-month price target for Taysha Gene is 11.571 USD, with a high estimate of 19 USD and a low estimate of 7 USD. 14 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +104.77% Upside potential.
What Is the TSHA Premarket Price?
TSHA's last pre-market stock price is 4.670 USD. The pre-market share volume is 1,620.000, and the stock has decreased by -0.040, or -0.850%.
What Is the TSHA After Hours Price?
TSHA's last after hours stock price is 4.671 USD, the stock has decreased by -0.039, or -0.830%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.